Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 3 from your keywords: subject="Palonosetron"
cover
Palonosetron in pediatric patients: A single-center, retrospective evaluation…
Comment Share
Ames M

Clinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refract…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for pre…
Comment Share
Saito M

d Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT3)-receptor antagonist that has shown better effi cacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy, and similar effi cacy to ondansetron in preventing CINV in patients receiving highly emetogenic chemotherapy. In this p…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Comparison of the Prophylactic Antiemetic Efficacy of Aprepitant Plus Palonos…
Comment Share
Choi EK

We compared the antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in patients after laparoscopic cholecystectomy. A total of 88, nonsmoking, female patients undergoing laparoscopic cholecystectomy were randomly allocated to 2 groups of 44 each who received palonosetron 0.075 mg (aprepitant plus palonosetron group) and ramosetron 0.3 mg (aprepitant plus ramos…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-